In general, knockdown of SEMA7A inhibits MPP+‐induced BV2 cell apoptosis and inflammation via PPAR‐γ activation and MAPK inactivation, which may provide a new therapy target for PD. This evidence concerns the gene SEMA7A and Parkinson disease.